Preoperative Management of Apixaban for L3-L4 Fusion Decompression Surgery

Rationale for 2-Day Interruption

The American College of Chest Physicians recommends stopping apixaban 2 days before L3-L4 fusion decompression surgery, as this procedure is classified as high bleeding risk, with significant hemorrhagic consequences including epidural hematoma and potential paralysis, and stopping apixaban 2 days preoperatively corresponds to approximately 4 half-lives of drug elimination, resulting in minimal residual anticoagulant effect at the time of surgery, in patients with normal or mildly impaired renal function 1, 2, 3
Stopping apixaban 2 days preoperatively applies to patients with normal or mildly impaired renal function (creatinine clearance ≥50 mL/min), and results in approximately 6% residual anticoagulant effect at the time of surgery 1, 3

For patients with moderate renal impairment (CrCl 30-50 mL/min), the interruption period should be extended to 3-4 days before surgery, as apixaban has 25% renal clearance, making it less dependent on kidney function than dabigatran, but impaired renal function still delays drug elimination 2, 3
Patients with declining renal function can accumulate apixaban and experience catastrophic bleeding complications, highlighting the importance of verifying renal function before finalizing the interruption plan 3

The last dose of apixaban should be taken on the morning 2 days before surgery, and bridging with heparin or low molecular weight heparin is not recommended during the perioperative interruption period, as the rapid offset and rapid onset of action of apixaban obviates the need for heparin bridging 1, 2
Bridging increases major bleeding risk without reducing stroke or systemic embolism, and the American College of Chest Physicians recommends against bridging anticoagulation during the perioperative interruption period 1, 3

Apixaban should be resumed 2-3 days (48-72 hours) after surgery, once adequate hemostasis is established, and at least 6 hours after the end of the surgical procedure, with consideration of starting with a reduced dose (2.5 mg twice daily) for the first 2-3 days in patients at high thromboembolism risk 2, 3
Therapeutic-dose apixaban should not be resumed while an epidural catheter is in place, to minimize the risk of bleeding complications 2